What is the share price of Bharat Parenterals Ltd (BPLPHARMA) today?
The share price of BPLPHARMA as on 13th June 2025 is ₹1217.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Bharat Parenterals Ltd (BPLPHARMA) share?
The past returns of Bharat Parenterals Ltd (BPLPHARMA) share are- Past 1 week: -7.76%
- Past 1 month: 16.38%
- Past 3 months: 17.69%
- Past 6 months: -25.85%
- Past 1 year: -15.76%
- Past 3 years: 259.02%
- Past 5 years: 430.54%
What are the peers or stocks similar to Bharat Parenterals Ltd (BPLPHARMA)?
The peers or stocks similar to Bharat Parenterals Ltd (BPLPHARMA) include:What is the dividend yield % of Bharat Parenterals Ltd (BPLPHARMA) share?
The current dividend yield of Bharat Parenterals Ltd (BPLPHARMA) is 0.07.What is the market cap of Bharat Parenterals Ltd (BPLPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bharat Parenterals Ltd (BPLPHARMA) is ₹838.06 Cr as of 13th June 2025.What is the 52 week high and low of Bharat Parenterals Ltd (BPLPHARMA) share?
The 52-week high of Bharat Parenterals Ltd (BPLPHARMA) is ₹1870 and the 52-week low is ₹802.What is the PE and PB ratio of Bharat Parenterals Ltd (BPLPHARMA) stock?
The P/E (price-to-earnings) ratio of Bharat Parenterals Ltd (BPLPHARMA) is -66.35. The P/B (price-to-book) ratio is 3.52.Which sector does Bharat Parenterals Ltd (BPLPHARMA) belong to?
Bharat Parenterals Ltd (BPLPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Bharat Parenterals Ltd (BPLPHARMA) shares?
You can directly buy Bharat Parenterals Ltd (BPLPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Bharat Parenterals Ltd
BPLPHARMA Share Price
1,217.602.00% (-24.80)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BPLPHARMA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BPLPHARMA Performance & Key Metrics
BPLPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -66.41 | 3.52 | 0.07% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
BPLPHARMA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BPLPHARMA Company Profile
Bharat Parenterals Limited is a pharmaceutical company that makes pharmaceutical formulations. Its products include general, beta-lactam, cephalosporins, antiretroviral, and veterinary.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.38%
2.38%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
72.00
72.00
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
81.25
81.25
BPLPHARMA Sentiment Analysis
BPLPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
BPLPHARMA Stock Summary · May 2025
Bharat Parenterals Limited is strategically enhancing its market position by focusing on complex injectables and critical care products, supported by a successful US FDA inspection that opens doors to high-value opportunities. The company is expanding its product pipeline significantly while maintaining operational flexibility, allowing for potential revenue growth despite current underutilization. Financially, it reported a robust revenue increase driven by milestone payments, although EBITDA margins have remained flat, indicating challenges in cost management. With a conservative approach to capital expenditures and a focus on strategic partnerships, Bharat aims to achieve operational break-even by FY '26, positioning itself for sustained growth in both regulated and emerging markets.
BPLPHARMA Stock Growth Drivers
BPLPHARMA Stock Growth Drivers
8Successful Regulatory Milestones
The company has achieved significant regulatory milestones, including the successful completion of a US FDA
Strong Financial Performance
Bharat Parenterals Limited reported robust financial results for FY '25, with stand-alone revenues increasing by
BPLPHARMA Stock Challenges
BPLPHARMA Stock Challenges
2Challenges in Out-Licensing Agreements
The company has faced difficulties in realizing milestone payments from out-licensing agreements, with only about
Uncertainty in CMO Revenue
The revenue from the Contract Manufacturing Organization (CMO) segment remains uncertain, as it is contingent
BPLPHARMA Forecast
BPLPHARMA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BPLPHARMA
BPLPHARMA
Income
Balance Sheet
Cash Flow
Annual Normal View
BPLPHARMA Income Statement
BPLPHARMA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 119.11 | 143.69 | 232.24 | 239.66 | 213.31 | 219.79 | 229.72 | 265.95 | 352.00 | 352.00 | ||||||||||
Raw Materials | 80.50 | 88.81 | 142.09 | 151.88 | 132.47 | 134.39 | 147.23 | 173.54 | 337.68 | 337.67 | ||||||||||
| Power & Fuel Cost | 1.79 | 2.62 | 2.70 | 3.19 | 3.10 | 3.21 | 3.75 | 4.69 | ||||||||||||
| Employee Cost | 11.37 | 12.94 | 15.37 | 15.58 | 14.75 | 15.37 | 18.00 | 22.78 | ||||||||||||
| Selling & Administrative Expenses | 6.40 | 12.36 | 21.64 | 21.65 | 14.04 | 13.87 | 23.67 | 28.80 | ||||||||||||
| Operating & Other expenses | 4.88 | 7.65 | 8.86 | 7.81 | 15.04 | 17.11 | 5.04 | 4.33 | ||||||||||||
EBITDA | 14.17 | 19.31 | 41.58 | 39.55 | 33.91 | 35.84 | 32.03 | 31.81 | 14.32 | 14.33 | ||||||||||
| Depreciation/Amortization | 5.79 | 5.57 | 6.13 | 5.88 | 6.03 | 6.66 | 5.88 | 9.02 | 35.32 | 35.32 | ||||||||||
| PBIT | 8.38 | 13.74 | 35.45 | 33.67 | 27.88 | 29.18 | 26.15 | 22.79 | -21.00 | -20.99 | ||||||||||
| Interest & Other Items | 0.91 | 0.94 | 0.87 | 0.86 | 0.77 | 1.31 | 2.60 | 4.07 | 12.95 | 12.95 | ||||||||||
| PBT | 7.47 | 12.80 | 34.58 | 32.81 | 27.11 | 27.87 | 23.55 | 18.72 | -33.95 | -33.94 | ||||||||||
| Taxes & Other Items | 0.59 | 3.68 | 13.35 | 8.65 | 6.74 | 6.83 | 7.10 | 4.21 | -21.32 | -21.32 | ||||||||||
| Net Income | 6.88 | 9.12 | 21.23 | 24.16 | 20.37 | 21.04 | 16.45 | 14.51 | -12.63 | -12.62 | ||||||||||
| EPS | 12.01 | 15.92 | 37.05 | 42.17 | 35.55 | 36.58 | 28.49 | 25.03 | -66.64 | -21.69 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.75 | 1.00 | 1.00 | 1.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.04 | — | -0.05 |
BPLPHARMA Company Updates
BPLPHARMA Stock Peers
BPLPHARMA Past Performance & Peer Comparison
BPLPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bharat Parenterals Ltd | -66.35 | 3.52 | 0.07% |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
BPLPHARMA Stock Price Comparison
Compare BPLPHARMA with any stock or ETFCompare BPLPHARMA with any stock or ETF
BPLPHARMA
BPLPHARMA Holdings
BPLPHARMA Shareholdings
BPLPHARMA Promoter Holdings Trend
BPLPHARMA Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 1.84%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BPLPHARMA Institutional Holdings Trend
BPLPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BPLPHARMA Shareholding Pattern
BPLPHARMA Shareholding Pattern
BPLPHARMA Shareholding History
BPLPHARMA Shareholding History
Foreign Institutions
smallcases containing BPLPHARMA stock
smallcases containing BPLPHARMA stock
Looks like this stock is not in any smallcase yet.
BPLPHARMA Events
BPLPHARMA Events
BPLPHARMA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BPLPHARMA Dividend Trend
No dividend trend available
BPLPHARMA Upcoming Dividends
BPLPHARMA Upcoming Dividends
No upcoming dividends are available
BPLPHARMA Past Dividends
BPLPHARMA Past Dividends
Cash Dividend
Ex DateEx DateJun 25, 2024
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Jun 25, 2024
Cash Dividend
Ex DateEx DateSep 25, 2023
Final
Final | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Sep 25, 2023
BPLPHARMA Stock News & Opinions
BPLPHARMA Stock News & Opinions
Articles & Videos
Earnings
Bharat Parenterals reports consolidated net loss of Rs 4.73 crore in the March 2025 quarter
Net Loss of Bharat Parenterals reported to Rs 4.73 crore in the quarter ended March 2025 as against net loss of Rs 0.30 crore during the previous quarter ended March 2024. Sales rose 53.32% to Rs 103.98 crore in the quarter ended March 2025 as against Rs 67.82 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 12.63 crore in the year ended March 2025 as against net profit of Rs 14.51 crore during the previous year ended March 2024. Sales rose 30.30% to Rs 340.38 crore in the year ended March 2025 as against Rs 261.22 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales103.9867.82 53 340.38261.22 30 OPM %2.141.47 -0.7910.37 - PBDT0.222.51 -91 1.3727.74 -95 PBT-8.30-1.36 -510 -33.9518.72 PL NP-4.73-0.30 -1477 -12.6314.51 PL Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Bharat Parenterals recommends Final Dividend
Bharat Parenterals announced that the Board of Directors of the Company at its meeting held on 12 May 2025, has recommended a Final Dividend of Rs.1 per share (i.e.10%), subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Bharat Parenterals to convene board meeting
Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Bharat Parenterals reports consolidated net loss of Rs 1.66 crore in the December 2024 quarter
Net loss of Bharat Parenterals reported to Rs 1.66 crore in the quarter ended December 2024 as against net profit of Rs 3.78 crore during the previous quarter ended December 2023. Sales rose 20.80% to Rs 72.26 crore in the quarter ended December 2024 as against Rs 59.82 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales72.2659.82 21 OPM %5.0511.05 - PBDT3.267.29 -55 PBT-5.505.47 PL NP-1.663.78 PL Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Bharat Parenterals to announce Quarterly Result
Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Bharat Parenterals reports consolidated net loss of Rs 7.51 crore in the September 2024 quarter
Net loss of Bharat Parenterals reported to Rs 7.51 crore in the quarter ended September 2024 as against net profit of Rs 3.52 crore during the previous quarter ended September 2023. Sales rose 19.76% to Rs 71.63 crore in the quarter ended September 2024 as against Rs 59.81 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales71.6359.81 20 OPM %-10.697.22 - PBDT-6.366.29 PL PBT-15.374.54 PL NP-7.513.52 PL Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Bharat Parenterals to announce Quarterly Result
Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Bharat Parenterals consolidated net profit declines 82.98% in the June 2024 quarter
Net profit of Bharat Parenterals declined 82.98% to Rs 1.28 crore in the quarter ended June 2024 as against Rs 7.52 crore during the previous quarter ended June 2023. Sales rose 32.33% to Rs 92.51 crore in the quarter ended June 2024 as against Rs 69.91 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales92.5169.91 32 OPM %4.8514.95 - PBDT4.2611.66 -63 PBT-4.7710.08 PL NP1.287.52 -83 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Bharat Parenterals announces board meeting date
Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 8 August 2024Powered by Capital Market - Live
10 months agoCapital Market - Live
Bharat Parenterals shares surge on Q1 results
1 year agoThe Hindu Businessline
Over the last 5 years, revenue has grown at a yearly rate of 2.75%, vs industry avg of 9.02%
Over the last 5 years, market share decreased from 0.11% to 0.07%
Over the last 5 years, net income has grown at a yearly rate of -7.33%, vs industry avg of 15.29%